These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38677723)

  • 1. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
    Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
    Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Machine Learning Approach for Predicting Biochemical Outcome After PSMA-PET-Guided Salvage Radiotherapy in Recurrent Prostate Cancer After Radical Prostatectomy: Retrospective Study.
    Janbain A; Farolfi A; Guenegou-Arnoux A; Romengas L; Scharl S; Fanti S; Serani F; Peeken JC; Katsahian S; Strouthos I; Ferentinos K; Koerber SA; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SK; Grosu AL; Ceci F; Henkenberens C; Kroeze SG; Guckenberger M; Belka C; Bartenstein P; Hruby G; Emmett L; Omerieh AA; Schmidt-Hegemann NS; Mose L; Aebersold DM; Zamboglou C; Wiegel T; Shelan M
    JMIR Cancer; 2024 Sep; 10():e60323. PubMed ID: 39303279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Harsini S; Martineau P; Plaha S; Saprunoff H; Chen C; Bishop J; Tyldesley S; Wilson D; Bénard F
    Cancer Imaging; 2024 Aug; 24(1):117. PubMed ID: 39210431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Outcomes from
    Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
    J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
    [No Abstract]   [Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
    Schmidt-Hegemann NS; Fendler WP; Ilhan H; Herlemann A; Buchner A; Stief C; Eze C; Rogowski P; Li M; Bartenstein P; Ganswindt U; Belka C
    Radiat Oncol; 2018 Mar; 13(1):37. PubMed ID: 29499730
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of relapse as determined by
    Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
    Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
    Armstrong WR; Kishan AU; Booker KM; Grogan TR; Elashoff D; Lam EC; Clark KJ; Steinberg ML; Fendler WP; Hope TA; Nickols NG; Czernin J; Calais J
    Eur Urol; 2024 Jul; 86(1):52-60. PubMed ID: 38290964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
    Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
    Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D
    BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
    Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2529-2536. PubMed ID: 36905411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
    Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of
    Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
    BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.